Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 6/20 | 0.61 |
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | HRH1 | P35367 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20536825 | 0.80 | HTR2A (0.61) | ANPEPHTR2AHRH1HTR2CHDAC4 | |
| SCHEMBL7124003 | 0.80 | ACP3 (0.47) | ANPEPHTR2A | |
| SCHEMBL30171215 | 0.78 | HTR2A (0.58) | ANPEPHTR2AHRH1HTR2CHDAC4 | |
| SCHEMBL2933755 | 0.77 | ANPEP (0.55) | ANPEPHTR2AHRH1CYP1A2HTR2C | |
| SCHEMBL2278230 | 0.76 | ANPEP (0.59) | ANPEPHTR2AHRH1CYP1A2HTR2C | |
| SCHEMBL30633009 | 0.76 | ANPEP (0.59) | ANPEPHTR2AHRH1CYP1A2HTR2C | |
| SCHEMBL7385396 | 0.76 | ANPEP (0.59) | ANPEPHTR2AHRH1CYP1A2HTR2C | |
| SCHEMBL18999729 | 0.76 | ANPEP (1.00) | ANPEPHTR2AHRH1CYP1A2HTR2C | |
| SCHEMBL6514594 | 0.76 | ANPEP (0.59) | ANPEPHTR2AHRH1CYP1A2HTR2C | |
| SCHEMBL2187484 | 0.76 | ANPEP (0.59) | ANPEPHTR2AHRH1CYP1A2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | ANPEP 1127/4885HTR2A 429/4885HRH1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.